Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf068 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Rupak Singla und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Tuberculosis, Multidrug-Resistant, Mycobacterium tuberculosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB, poses significant threats to TB treatment effectiveness.
Methods
The National Institute of Tuberculosis and Respiratory Diseases in Delhi and the Médecins Sans Frontières clinic in Mumbai provide BDQ, delamanid, and carbapenem-based regimens for patients with suspected or confirmed treatment failure. BDQ phenotypic drug-susceptibility testing (DST) was performed for all BDQ-exposed patients. Treatment regimens were individualized based on exposure history, comorbidities, drug interactions, prior adverse drug reactions, and DST results.
Results
Of 117 BDQ-exposed patients from December 2020–December 2022, 42 (36%) exhibited a BDQ-resistant strain. Median (IQR) age was 24 (22–32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ-resistant strain were older (median age: 27 vs 23 years; P = .04), more likely to have lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1–3.1; P = .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5–3.6; P = .001). Overall, 102 patients initiated treatment. Patients with BDQ-resistance had higher risk of unfavorable outcomes compared with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5–2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance experienced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up.
Conclusions
The study highlights a concerning rate of BDQ-resistance among previously treated patients, resulting in poor treatment outcomes. To prevent treatment failure, we recommend implementing BDQ-DST, developing affordable and accurate rapid tests for BDQ-resistance, and intensifying research and development efforts for newer TB drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
- Médecins Sans Frontières, Mumbai, India.
- Jupiter Hospital, Mumbai, India.
- Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.
- Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
ORCID-Profile: Samsuddin Khan, Vijay Chavan, Raman Mahajan, Neeta Singla, Petros Isaakidis
Zitieren
APA
Singla, R., Khan, S., Silsarma, A., Chavan, V., Mahajan, R., Mansoor, H., Devan, R. K., Singla, N., Bhalla, M., Kumar, G., Singh, P., Iyer, A., Morales, M., Devkota, S. C., Dalal, A., Spencer, H., & Isaakidis, P. (2025). Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf068
Vancouver
Singla R, Khan S, Silsarma A, Chavan V, Mahajan R, Mansoor H, et al. Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf068
BibTeX
@article{Singla2025,
author = {Singla, Rupak and Khan, Samsuddin and Silsarma, Arunima and Chavan, Vijay and Mahajan, Raman and Mansoor, Homa and Devan, Ravindra Kumar and Singla, Neeta and Bhalla, Manpreet and Kumar, Gavish and Singh, Pramila and Iyer, Aparna and Morales, Mabel and Devkota, Satish Chandra and Dalal, Alpa and Spencer, Hannah and Isaakidis, Petros},
title = {Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf068}
}
EUVIMED